Search clinical trials for: Isentress

Total 126 results

Centre de Recherches et d'Etude sur la Pathologie...

Recruiting

HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label (DORAL)

HIV Infections

France
Ottawa Hospital Research Institute

Recruiting

The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir. (RCPK)

Calcium Supplementation in HIV Patients Using Raltegravir

Canada
University of Zurich

Recruiting

Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study

HIV Infections

Switzerland
IrsiCaixa

Completed

Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors

HIV-1 Infection

Spain
Weill Medical College of Cornell University
National Institute on Aging (NIA)

Completed

Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF

Heart Failure | Heart Disease | Heart Failure, Diastolic | Heart Failure With Preserved Ejection Fraction | Cardiac Failure

United States
University of North Carolina, Chapel Hill
Merck Sharp & Dohme LLC

Withdrawn

The Effect of Pregnancy on the PK of Isentress®: A Longitudinal Investigation in the Second and Third Trimesters

Pregnancy | HIV
University of Alberta
Merck Sharp & Dohme LLC

Completed

Combination Antiretroviral Therapy (cART) for PBC

Primary Biliary Cholangitis

Canada
Imperial College London
Medical Research Council; University of Oxford; Guy's and St Thomas' NHS Foundation... and other collaborators

Completed

Research In Viral Eradication of HIV Reservoirs (RIVER)

HIV

United Kingdom
McGill University Health Centre/Research Institute...
Merck Sharp & Dohme LLC

Completed

Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients

Fatty Liver | HIV | Nonalcoholic Steatohepatitis

Canada
University of Maryland, Baltimore
Merck Sharp & Dohme LLC

Completed

R5 Integrase Study in HIV-1 Naive Patients

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection

HIV Infections

United States, Thailand, Puerto Rico, Brazil, South Africa
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents

HIV Infections

United States, Puerto Rico, South Africa, Argentina, Brazil, Botswana
Helsinki University Central Hospital
Merck Sharp & Dohme LLC

Completed

Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir (OBERAL)

Fatty Liver | Metabolic Syndrome | HIV Seropositivity

Finland
University of Hawaii
Oxford University Clinical Research Unit, Vietnam; Hospital for Tropical Diseases... and other collaborators

Completed

Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection

HIV Infection | Hepatitis C, Chronic

Vietnam
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study of Options for Second-Line Effective Combination Therapy (SELECT) (SELECT)

HIV-1 Infection

Peru, Kenya, Malawi, Brazil, South Africa, Zimbabwe, India, Thailand, Tanzania
Guy's and St Thomas' NHS Foundation Trust

Completed

Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection (R-PrEP)

Hiv

United Kingdom
National Jewish Health
Merck Sharp & Dohme LLC

Completed

Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen

HIV

United States
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir (OPAL)

HIV Infections | HCV Infections

Netherlands
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER) (GINGER)

Depression | HIV Infections | Mild Cognitive Impairment

Netherlands
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA) (GRAPPA)

HIV Infections

Netherlands
Radboud University Medical Center

Completed

Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL). (RECITAL)

Depression | HIV

Netherlands
University of California, San Diego
Merck Sharp & Dohme LLC; Abbott; California HIV/AIDS Research Program

Completed

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

HIV Infections

United States
Nantes University Hospital

Completed

QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient (QDISS)

Virus-HIV

France
Imperial College London

Completed

The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age

HIV

United Kingdom
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)

Human Immunodeficiency Virus (HIV) Infection

Japan
Hospital Clinic of Barcelona

Completed

Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients. (RALDAR)

Integrase Inhibitors, HIV; HIV PROTEASE INHIB

Spain
Kirby Institute
Merck Sharp & Dohme LLC; amfAR, The Foundation for AIDS Research; Abbott

Completed

A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (SECOND-LINE)

HIV Infections

Taiwan, Australia, Argentina, Singapore, India, France, South Africa, Chile, Germany, Hong Kong, Ireland, Malaysia, Mexico, New Zealand, Nigeria, Peru, United Kingdom
University of Modena and Reggio Emilia

Completed

A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL)

HIV Infection

Italy
Allina Health System

Completed

Raltegravir Kaletra Pharmacokinetics (RAL-KAL)

Healthy

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Completed

A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE)

HIV-1 Infection

Kenya, Brazil, South Africa, Uganda, Zimbabwe, India, Malawi, Haiti, Thailand, Peru
Taipei Veterans General Hospital, Taiwan

Completed

Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients

HIV-1 Infection

Taiwan
R-Pharm
Almedis

Completed

A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs

Healthy

Russian Federation
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation (RAPID)

HIV
University of North Carolina, Chapel Hill
Merck Sharp & Dohme LLC

Completed

Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults

Human Immunodeficiency Virus

United States
Giovanni Di Perri
University of Turin, Italy; University of Milan

Terminated

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir (RALBAT)

HIV Infection | Osteopenia

Italy
George Washington University

Terminated

Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

HIV Infections

United States
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295)

HIV Infections
Merck Sharp & Dohme LLC
Kaiser Permanente

Completed

Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)

HIV-1 Infections
Merck Sharp & Dohme LLC
Covance

Completed

A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)

HIV Infection
Kaiser Permanente
Merck Sharp & Dohme LLC

Completed

Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects (CHEER)

HIV Infections

United States
University of Zurich
Merck Sharp & Dohme LLC; Swiss HIV Cohort Study

Completed

Raltegravir in the Swiss HIV Cohort Study

HIV Infection

Switzerland
University of North Carolina, Chapel Hill

Completed

A Key Link for Transmission Prevention (MP3)

HIV

Malawi
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Terminated

Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV

HIV Infection | Tuberculosis

Peru, Brazil, South Africa, Haiti, Kenya
ANRS, Emerging Infectious Diseases

Completed

Evaluation of Raltegravir During the Third Trimester of Pregnancy (ANRS 160 RalFE)

HIV-1 Infection | PREGNANCY

France
University of Nebraska

Completed

Measurement of Plasma and Intracellular Concentrations of Raltegravir

HIV

United States
Massachusetts General Hospital
Merck Sharp & Dohme LLC

Completed

Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen

HIV | Neurotoxicity | HIV-associated Neurocognitive Disorder

United States
University of Colorado, Denver

Completed

Effect of Antacids on the Pharmacokinetics of Raltegravir

HIV Infections

United States
St Stephens Aids Trust
Merck Sharp & Dohme LLC

Completed

Renal Integrase Study

HIV

United Kingdom
Queen Mary University of London
Merck Sharp & Dohme LLC

Completed

Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis (INSPIRE)

Relapsing Remitting Multiple Sclerosis

United Kingdom
University of California, Davis

Completed

Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy

HIV Infections | AIDS

United States

Search clinical trials for: Isentress

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations